Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].
Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F; Groupe de travail du référentiel Association francophone pour les soins oncologiques de support (AFSOS) sur les nausées-vomissements induits par les traitements anti-cancéreux. Jovenin N, et al. Among authors: mayeur d. Bull Cancer. 2019 May;106(5):497-509. doi: 10.1016/j.bulcan.2019.02.002. Epub 2019 Mar 25. Bull Cancer. 2019. PMID: 30922554 Review. French.
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F. Ladoire S, et al. Among authors: mayeur d. Eur J Cancer. 2022 Apr;165:13-24. doi: 10.1016/j.ejca.2022.01.005. Epub 2022 Feb 1. Eur J Cancer. 2022. PMID: 35189537 Free PMC article.
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM, Jaillon-Abraham C, Lucas V, Chrétien Y, Mayeur D, Di Palma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Larregain D, Ecstein E, Untereiner M, Andrieu JM. Tourani JM, et al. Among authors: mayeur d. Bull Cancer. 1997 Apr;84(4):351-6. Bull Cancer. 1997. PMID: 9238157 Free article. Clinical Trial. French.
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C. Tourani JM, et al. Among authors: mayeur d. J Clin Oncol. 1998 Jul;16(7):2505-13. doi: 10.1200/JCO.1998.16.7.2505. J Clin Oncol. 1998. PMID: 9667271 Clinical Trial.
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.
Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F. Ladoire S, et al. Among authors: mayeur d. Eur J Cancer. 2021 May;148:359-370. doi: 10.1016/j.ejca.2021.02.027. Epub 2021 Feb 27. Eur J Cancer. 2021. PMID: 33780664 Free PMC article.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
62 results